Benitec Biopharma Inc (BNTC)

$8.99

+0.03

(+0.33%)

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $8.88
    $9.47
    $8.99
    downward going graph

    1.22%

    Downside

    Day's Volatility :6.23%

    Upside

    5.07%

    downward going graph
  • $1.86
    $10.88
    $8.99
    downward going graph

    79.31%

    Downside

    52 Weeks Volatility :82.9%

    Upside

    17.37%

    downward going graph

Returns

PeriodBenitec Biopharma IncIndex (Russel 2000)
3 Months
33.78%
0.0%
6 Months
215.44%
0.0%
1 Year
150.63%
0.0%
3 Years
-86.01%
-19.9%

Highlights

Market Capitalization
85.5M
Book Value
$4.22
Earnings Per Share (EPS)
-9.6
PEG Ratio
0.0
Wall Street Target Price
19.67
Profit Margin
0.0%
Operating Margin TTM
-307028.56%
Return On Assets TTM
-115.7%
Return On Equity TTM
-267.59%
Revenue TTM
7.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
12.5%
Gross Profit TTM
75.0K
EBITDA
-21.4M
Diluted Eps TTM
-9.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.1
EPS Estimate Next Year
-1.89
EPS Estimate Current Quarter
-0.78
EPS Estimate Next Quarter
-0.4

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Benitec Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 118.8%

Current $8.99
Target $19.67

Technicals Summary

Sell

Neutral

Buy

Benitec Biopharma Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Benitec Biopharma Inc
Benitec Biopharma Inc
24.69%
215.44%
150.63%
-86.01%
-94.74%
Moderna, Inc.
Moderna, Inc.
-11.5%
19.92%
-1.43%
-63.9%
737.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.78%
11.32%
45.17%
82.69%
236.57%
Novo Nordisk A/s
Novo Nordisk A/s
-6.33%
26.68%
64.47%
198.6%
438.18%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.24%
14.68%
37.33%
146.48%
182.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Benitec Biopharma Inc
Benitec Biopharma Inc
NA
NA
0.0
-5.1
-2.68
-1.16
NA
4.22
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.55
31.55
1.46
44.35
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.95
45.95
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.16
32.16
0.53
17.04
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Benitec Biopharma Inc
Benitec Biopharma Inc
Buy
$85.5M
-94.74%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.9B
737.94%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.9B
236.57%
31.55
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.6B
438.18%
45.95
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.0B
182.87%
32.16
39.46%

Insights on Benitec Biopharma Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 54.0K → 6.0K (in $), with an average decrease of 50.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -6.79M → -4.27M (in $), with an average increase of 58.9% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.7% return, outperforming this stock by 279.7%

Institutional Holdings

  • Franklin Resources Inc

    6.28%
  • HHG PLC

    2.61%
  • Suvretta Capital Management, LLC

    2.18%
  • Adage Capital Partners Gp LLC

    2.02%
  • Vanguard Group Inc

    0.18%
  • Morgan Stanley - Brokerage Accounts

    0.13%

Company Information

benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.

Organization
Benitec Biopharma Inc
Employees
16
CEO
Dr. Jerel A. Banks M.D., Ph.D.
Industry
Health Technology

FAQs